Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Esophageal adenocarcinoma (EAC) is a poor-prognosis cancer type with rapidly rising incidence. Understanding of the genetic events driving EAC development is limited, and there are few molecular biomarkers for prognostication or therapeutics. Using a cohort of 551 genomically characterized EACs with matched RNA sequencing data, we discovered 77 EAC driver genes and 21 noncoding driver elements. We identified a mean of 4.4 driver events per tumor, which were derived more commonly from mutations than copy number alterations, and compared the prevelence of these mutations to the exome-wide mutational excess calculated using non-synonymous to synonymous mutation ratios (dN/dS). We observed mutual exclusivity or co-occurrence of events within and between several dysregulated EAC pathways, a result suggestive of strong functional relationships. Indicators of poor prognosis (SMAD4 and GATA4) were verified in independent cohorts with significant predictive value. Over 50% of EACs contained sensitizing events for CDK4 and CDK6 inhibitors, which were highly correlated with clinically relevant sensitivity in a panel of EAC cell lines and organoids.

Original publication

DOI

10.1038/s41588-018-0331-5

Type

Journal article

Journal

Nature genetics

Publication Date

03/2019

Volume

51

Pages

506 - 516

Addresses

MRC cancer unit, Hutchison/MRC research Centre, University of Cambridge, Cambridge, UK.

Keywords

Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Consortium, Humans, Adenocarcinoma, Esophageal Neoplasms, Cohort Studies, Gene Expression Profiling, Genomics, Gene Expression Regulation, Neoplastic, Mutation, Female, Male, DNA Copy Number Variations, Exome, Biomarkers, Tumor